FuzzyBot: Importing a new version from external source

2024-02-14T00:56:20Z

Importing a new version from external source

New page

=== ISIS 388626 ===
According to preliminary findings of a novel method of SGLT-2 inhibition, the [[Sense (molecular biology)|antisense]] [[oligonucleotide]] ISIS 388626 improved plasma glucose in rodents and dogs by reducing [[mRNA]] expression in the proximal renal tubules by up to 80% when given once a week. It did not affect SGLT-1. A study results on long-term use of ISIS 388626 in [[Animal testing on non-human primates|non-human primates]] observed more than 1000 fold increase in [[Glycosuria|glucosuria]] without any associated hypoglycemia. This increase in glucosuria can be attributed to a dose-dependent reduction in the expression of SGLT-2, where the highest dose led to more than 75% reduction. In 2011, [[Ionis Pharmaceuticals]] initiated a [[Phases of clinical research|clinical phase 1 study]] with ISIS-SGLT-2RX, a 12-nucleotide antisense [[oligonucleotide]]. Results from this study were published in 2017 and the treatment was "associated with unexpected renal effects". The authors concluded that "Before the concept of antisense-mediated blocking of SGLT2 with ISIS 388626 can be explored further, more preclinical data are needed to justify further investigations."

Translations:Discovery and development of gliflozins/19/en - Revision history

FuzzyBot: Importing a new version from external source